Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

BACKGROUND: The oral IP receptor agonist selexipag is approved for the long-term treatment of pulmonary arterial hypertension (PAH). Treatment interruptions should be avoided due to the progressive nature of the disease. An intravenous (IV) formulation of selexipag was developed to provide a treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Klose, Hans, Chin, Kelly M., Ewert, Ralf, Gall, Henning, Parambil, Joseph, Poch, David, Seyfarth, Hans-Jürgen, Axelsen, Lene N., Hsu Schmitz, Shu-Fang, Stein, Claudia, Preston, Ioana R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856757/
https://www.ncbi.nlm.nih.gov/pubmed/33536021
http://dx.doi.org/10.1186/s12931-020-01594-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856757/
https://www.ncbi.nlm.nih.gov/pubmed/33536021
http://dx.doi.org/10.1186/s12931-020-01594-8

Ejemplares similares